Sunday - May 4, 2025

LOGIN  |  REGISTER
Chimerix
Terns Pharmaceuticals

Veradigm to Present at the 2023 J.P. Morgan Healthcare Conference

January 06, 2023 | Last Trade: US$4.20 0.00 0.00

Veradigm Inc. (Nasdaq:MDRX), formerly Allscripts Healthcare Solutions Inc., announced today that Rick Poulton, Veradigm Chief Executive Officer, will present at the 2023 J.P. Morgan Healthcare conference on Wednesday, January 11, 2023 at 3:45 PST.

The live audio webcast and replay can be accessed at the J.P. Morgan public link here.

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully. For more information on Veradigm, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube

C4 Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page